Rigor Reviewed

Rigor-Reviewed Manuscript

Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial.

Name: Αlpha¹ Rigor Record — Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial.
Item: Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial.
Rating: 96
Author: Αlpha¹

Mueller S, Dinges SMT, Gass F, Fegers-Wustrow I, Treitschke J, von Korn P, Boscheri A, Krotz J, Freigang F, Dubois C, Winzer EB, Linke A, Edelmann F, Feuerstein A, Wolfram O, Schäfer K, Verket M, Wolfarth B, Dörr M, Wachter R, Hackenberg B, Rust S, Nebling T, Amelung V, Halle M

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted multicenter RCT with rigorous randomization, pre-specified analyses, and transparent reporting. The main weakness is the vague data availability statement, and there are minor copyedit issues including a potential percentage inconsistency in Table 1.

Both reviewers classified the study as interventional (RCT), and no divergence was present. The evaluation covered the full text, including methods, results, and discussion. Non-applicable sub-criteria (e.g., animal housing, cell lines) were excluded. The statistics verification covered only 4 tests; the remaining statistics were not machine-verified.

7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies and meta-analyses on lifestyle interventions in CHD and T2DM, acknowledges the limited evidence in combined conditions, and clearly states the hypothesis. Limitations of prior research (e.g., transient effects, low adherence) are explicitly discussed and addressed by the telemedicine-supported design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking the intervention to the study objectives.

Evidence

paraphrase[Introduction, paragraph 1-3]

“However, despite evidence of physical activity interventions in patients with standalone conditions, only three trials to date have investigated the effects of exercise training compared to a control group in patients with both conditions. These trials did not show significant group differences in changes of HbA1c.”

paraphrase[Introduction, paragraph 4]

“Telemedicine-supported home-based approaches have emerged as a potentially effective and cost-efficient alternative, also reaching patients who may not be able to take part in supervised on-site programs.”

paraphrase[Introduction, paragraph 5]

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking the intervention to the study objectives.

Evidence

paraphrase[Introduction, paragraph 1-3]

direct quote[Introduction, last paragraph]

“We hypothesized that 6 months of individualized, telemedicine-supported, home-based exercise training and nutritional counseling with regular feedback via telephone and e-mail, as well as health literacy education, will significantly reduce HbA1c compared to usual care and that these improvements can be maintained over an additional 6 months without regular feedback and health literacy education.”